Tags: Bind | Cancer | Drug | Amgen

Bind Therapeutics Ends Cancer Drug Deal with Amgen

Wednesday, 02 Jul 2014 06:00 PM

Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc. to develop targeted cancer therapy due to unsatisfactory results.

Bind's shares fell 15 percent to $10.95 in extended trading on Wednesday. Amgen's shares were little changed from their close of $121.03.

"Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both collaborators have agreed that the program will not be continued," Bind's Chief Executive Scott Minick said in a statement.

The company had entered into a twelve-month collaboration agreement with Amgen in January 2013 to develop cancer treatments using Bind's nanotechnology platform and an Amgen compound.

© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc. to develop targeted cancer therapy due to unsatisfactory results.
Bind, Cancer, Drug, Amgen
107
2014-00-02
Wednesday, 02 Jul 2014 06:00 PM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved